EU health ministers on 16 June 2026 broadly supported the Critical Medicines Act and biotechnology as strategic, but clashed over the lack of an ex ante impact assessment for the European Biotech Act directive, with several ministers questioning the speed of the legislative process. The EPSCO Health Council, chaired by the Cyprus Presidency, saw Commissioner for Health and Food Safety Olivér Várhelyi reject calls for further delay, warning that postponement risks losing industry. Várhelyi defended the existing impact analysis and stressed that the package, which includes a general approach on the Biotech Act directive, is a record-speed achievement tied to competitiveness and supply security.
Disputes emerged over supplementary protection certificate (SPC) extension, with some ministers concerned about cost implications. Várhelyi defended the SPC extension as targeted for biotechnological inventions with conditionalities, downplaying cost concerns. On industrial anchoring versus affordability, Cyprus stressed preserving universal access without undermining public health budgets, while Várhelyi emphasized keeping innovation and manufacturing in Europe. On EU-level coordination, Cyprus reported calls for greater cooperation, but Várhelyi firmly noted that health system organization remains a national competence.
Regarding external pressures such as most-favoured-nation (MFN) treatment, Cyprus and Várhelyi indicated that member states tasked the Commission with analysis rather than immediate action, with a commitment to deliver before summer. On health security, Várhelyi confirmed ministers' support for ECDC and Health Security Committee work on Ebola. On the urban wastewater treatment directive, Várhelyi urged careful implementation to avoid shortages or offshoring.
Consensus included broad support for the Critical Medicines Act, biotechnology as strategic, and simplifying medical devices rules. Next steps: Cyprus will compile views into a note for the incoming Irish Presidency, and the Commission will produce an MFN analysis before summer. Affected stakeholders include pharmaceutical companies facing accelerated regulatory timelines, national health systems balancing innovation costs with universal access, patients potentially benefiting from faster access to biotech medicines, and biotech innovators who may gain from SPC extension but face uncertainty over impact assessment gaps.